Due to the frequent perioperative use of ketorolac tromethamine and its ability to minimize postoperative opioid requirements, it is important to continually reassess harms associated with its use. Our primary objective was to investigate the extent of harms reporting in systematic reviews (SRs) on ketorolac for perioperative pain. In May 2022, we conducted a search of major databases, MEDLINE (Pubmed and Ovid), Embase, Epistemonikos, and the Cochrane Database of Systematic Reviews to identify eligible SRs on ketorolac for perioperative pain. Screening and data extraction was performed in masked, duplicate fashion. AMSTAR-2 was used to appraise the methodological quality of included SRs. Corrected covered area (CCA) was calculated to determine overlap of primary studies between SR dyads. A total of 28 SRs evaluating 630 primary studies met inclusion criteria. Seven SRs (7/28, 25%) reported no harms and 17 SRs (17/28, 60.7%) reported ≤ 50% of harms items. A significant association was found between completeness of harms reporting and whether harms were specified as a primary outcome (P 50% but neither reported harms. The extent of harms reporting in SRs was inadequate. Given the importance that SRs have on guiding perioperative decision-making, it is essential to improve the completeness of harms reporting.
|Original language||American English|
|State||Published - 4 Nov 2022|
|Event||111th Annual Technical Meeting, Oklahoma Academy of Science - Oklahoma State University Center for Health Sciences, Tulsa, United States|
Duration: 4 Nov 2022 → 4 Nov 2022
|Conference||111th Annual Technical Meeting, Oklahoma Academy of Science|
|Abbreviated title||OAS Meeting 2022|
|Period||4/11/22 → 4/11/22|